Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
The adoptive transfer of allogeneic CAR NK cells holds great promise as an anticancer modality due to the relative ease of manufacturing and genetic modification of NK cells, which translates into affordable pricing. Compared to the pronounced efficacy of CAR T cell therapy in the treatment of B cel...
Enregistré dans:
Auteurs principaux: | Sergey Kulemzin, Igor Evsyukov, Tatiana Belovezhets, Alexander Taranin, Andrey Gorchakov |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a2b72c875ab4462e8f8d81b911b3bbf0 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
par: Lara Herrera, et autres
Publié: (2021) -
Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
par: Erica L. Heipertz, et autres
Publié: (2021) -
Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy
par: Hawkins ER, et autres
Publié: (2021) -
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
par: Cristina Aparicio, et autres
Publié: (2021) -
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
par: Christopher Sloas, et autres
Publié: (2021)